Is TG Therapeutics a good stock to buy?

TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. TG Therapeutics has seen significant volatility in its stock price over the past few years.

Who owns TG Therapeutics Inc?

Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC. TGTX | Complete TG Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Is TG Therapeutics (tgtx) listed on the NASDAQ?

TG Therapeutics, Inc. is currently listed on NASDAQ under TGTX. One share of TGTX stock can currently be purchased for approximately $17.96. Is TG Therapeutics, Inc. listed on the NASDAQ or NYSE? TG Therapeutics, Inc. is listed on the NASDAQ as (NASDAQ:TGTX). What is TG Therapeutics, Inc.'s stock symbol?